Form 4: MiMedx Group Executive Receives Stock and Option Grants

Ricci S. Whitlow, Chief Operating Officer of MiMedx Group, received grants of restricted stock and stock options on March 3, 2025.

Summary

• Ricci S. Whitlow, the Chief Operating Officer of MiMedx Group, Inc., reported changes in beneficial ownership of securities.
• On March 3, 2025, Whitlow acquired 45,929 shares of common stock through a restricted stock grant and 36,486 stock options.
• The restricted stock vests fully on the third anniversary of the grant date, contingent upon continued employment.
• The stock options vest 25% on each anniversary of the grant date, also contingent upon continued employment.
• Following these transactions, Whitlow beneficially owns 448,948 shares of common stock and 107,241 stock options.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, suggesting stability and alignment of interests. It's a neutral-positive event.

Positives

• The grant of restricted stock and stock options aligns the executive's interests with those of the shareholders.
• Vesting schedules tied to continued employment incentivize long-term commitment from the COO.

Risks

• The value of the stock and options is subject to market fluctuations and the company's performance.
• Failure to meet continued employment requirements would result in forfeiture of unvested shares and options.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.

Industry Context

Grants of stock options and restricted stock are common practices in the industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in publicly traded companies, particularly in the biotech and medical device sectors.
• Companies like Integra LifeSciences and Organogenesis also utilize stock options and restricted stock units to align executive incentives with shareholder value.
• The vesting schedules described are fairly standard, with vesting periods of three to four years being common.

Stakeholder Impact

• Shareholders may view the grants positively as they align executive interests with company performance.
• Employees may see the grants as a sign of confidence in the company's future.

Key Dates